Pulmonx Co. (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 5,779 Shares

Pulmonx Co. (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 5,779 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $7.13, for a total value of $41,204.27. Following the sale, the insider now owns 285,278 shares of the company’s stock, valued at approximately $2,034,032.14. This trade represents a 1.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Pulmonx Stock Performance

Shares of NASDAQ LUNG opened at $8.19 on Thursday. The stock has a market capitalization of $325.93 million, a price-to-earnings ratio of -5.69 and a beta of 0.50. Pulmonx Co. has a 52-week low of $5.46 and a 52-week high of $10.01. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The stock’s fifty day simple moving average is $6.93 and its 200 day simple moving average is $6.93.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The firm had revenue of $23.77 million for the quarter, compared to the consensus estimate of $22.29 million. As a group, sell-side analysts forecast that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wells Fargo & Company cut their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Citigroup reiterated a “neutral” rating and set a $7.50 price target (down from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Pulmonx presently has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C bought a new stake in shares of Pulmonx during the 4th quarter worth about $10,421,000. FMR LLC boosted its stake in shares of Pulmonx by 11.2% during the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock worth $48,686,000 after acquiring an additional 591,859 shares in the last quarter. PFM Health Sciences LP bought a new stake in shares of Pulmonx during the 3rd quarter worth about $3,058,000. Altium Capital Management LLC boosted its stake in shares of Pulmonx by 63.0% during the 4th quarter. Altium Capital Management LLC now owns 815,000 shares of the company’s stock worth $5,534,000 after acquiring an additional 315,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in shares of Pulmonx during the 3rd quarter worth about $1,711,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.